Analyst firms · UBS · ARGX
UBS ARGX price target and rating history
argenx SE (ARGX) · Health Care
UBS rates argenx SE (ARGX) Buy with a $1,400 price target, as of its latest action on Aug 26, 2026. It has published 3 rating actions on ARGX since May 2023, including 1 upgrade and 1 downgrade. Across 3 firms with a ARGX price target in the last 12 months, the median target is $1,185. UBS's $1,400 is 18% above that.
- Current rating
- Buy
- Price target
- $1,400
- Median target, all firms
- $1,185
- Actions on ARGX
- 3
UBS price target on ARGX
Every UBS rating on ARGX
- Aug 26, 2026
- Jul 24, 2023
- May 31, 2023
How other firms rate ARGX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Buy | $1,400 | Aug 26, 2026 |
| Deutsche Bank | Hold | Aug 24, 2026 | |
| Guggenheim | Buy | $1,185 | Aug 4, 2026 |
| Robert W. Baird | Neutral | $858 | Dec 18, 2025 |
| Wolfe Research | Peer Perform | Nov 24, 2025 |
Questions about UBS and ARGX
- What is UBS's price target for ARGX?
- UBS's latest stated price target for argenx SE (ARGX) is $1,400, from its action on Aug 26, 2026.
- What is UBS's rating on ARGX?
- UBS rates ARGX Buy, a bullish rating, as of Aug 26, 2026.
- When did UBS last change its view on ARGX?
- On Aug 26, 2026, UBS upgrades to Buy from Neutral, price target $1,400.
- How does UBS's ARGX target compare with other analysts?
- Across 3 firms with a ARGX price target in the last 12 months, the median target is $1,185. UBS's $1,400 is 18% above that.
More ARGX rating histories
All UBS ratingsARGX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.